Log in
Enquire now
‌

US Patent 9987223 Compositions and methods for treating pterygium

Patent 9987223 was granted and assigned to CLOUDBREAK THERAPEUTICS LLC on June, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
CLOUDBREAK THERAPEUTICS LLC
CLOUDBREAK THERAPEUTICS LLC
Current Assignee
CLOUDBREAK THERAPEUTICS LLC
CLOUDBREAK THERAPEUTICS LLC
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9987223
Date of Patent
June 5, 2018
Patent Application Number
15474620
Date Filed
March 30, 2017
Patent Citations Received
‌
US Patent 11911379 Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
0
‌
US Patent 11666533 Emulsion formulations of multikinase inhibitors
0
Patent Primary Examiner
‌
Theodore R West
Patent abstract

Compositions and methods for inducing pterygium regression from visual axis/central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9987223 Compositions and methods for treating pterygium

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.